Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
NCT ID: NCT00073047
Last Updated: 2009-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
150 participants
INTERVENTIONAL
2003-04-30
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
NCT02118584
Research Study in Patients With Severe Ulcerative Colitis
NCT00032305
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017
Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis
NCT05907330
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Daclizumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mayo score of 5-10 (inclusive)
* Not used any investigational therapy for 30 days prior to screening
* No treatment with monoclonal antibody therapy within 12 weeks of screening
* No prior treatment with daclizumab
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Facet Biotech
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Associates
Huntsville, Alabama, United States
Advanced Medical Research Institute
Anaheim, California, United States
Research Foundation of America
Los Angeles, California, United States
Western Gastroenterology Group
Los Angeles, California, United States
Cedar Sinai Medical Center
Los Angeles, California, United States
GVAMC
Gainesville, Florida, United States
Clinical Research Associates
Hollywood, Florida, United States
Physician Office
Jacksonville, Florida, United States
Mount Sinai Medical Center
North Miami Beach, Florida, United States
Atlanta Gastroenterology Associates
Atlanta, Georgia, United States
The University of Chicago Hospital
Chicago, Illinois, United States
University of Kentucky Chandler Medical Center
Lexington, Kentucky, United States
Drug Research Services, Inc.
Metairie, Louisiana, United States
Medlantic Investigators Network
Annapolis, Maryland, United States
St. Louis Center for Clinical Research
St Louis, Missouri, United States
Long Island Clinical Research Associates
Great Neck, New York, United States
New York Center for Clinical Research
Lake Success, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Consultants for Clinical Research
Cincinnati, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Oklahoma Foundation for Digestive Research
Oklahoma City, Oklahoma, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Columbia Gastro Associates
Columbia, South Carolina, United States
Memphis Gastroenterology Group, P.C.
Memphis, Tennessee, United States
Nashville Medical Research
Nashville, Tennessee, United States
Fletcher Allen Health Care
South Burlington, Vermont, United States
Digestive and Liver Disease Specialists
Norfolk, Virginia, United States
Richmond GI Research Group
Richmond, Virginia, United States
McGuire DVAMC
Richmond, Virginia, United States
Wisconsin Center for Advanced Research
Milwaukee, Wisconsin, United States
Universitair Ziekenhuis Gasthuisberg
Leuven, , Belgium
University of Alberta
Edmonton, Alberta, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
London Health Science Center
London, Ontario, Canada
Montreal General Hospital
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.